Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850395 | 0.99 | MAPT (0.37) | MAPTAPPSLC16A3SLC16A1NPC1 | |
| SCHEMBL20850288 | 0.96 | MAPT (0.34) | MAPTAPPSLC16A3SLC16A1NPC1 | |
| SCHEMBL20850098 | 0.95 | SLC16A3 (0.36) | MAPTAPPSLC16A3SLC16A1NPC1 | |
| SCHEMBL20850299 | 0.94 | MAPT (0.32) | MAPTAPPNPC1CYP1A2CYP2C9 | |
| SCHEMBL20850284 | 0.91 | SLC16A3 (0.34) | MAPTAPPSLC16A3SLC16A1NPC1 | |
| SCHEMBL20850283 | 0.89 | SLC16A3 (0.33) | MAPTAPPSLC16A3SLC16A1NPC1 | |
| SCHEMBL20850286 | 0.89 | MAPT (0.34) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL20850389 | 0.88 | SLC16A3 (0.32) | MAPTAPPSLC16A3SLC16A1NPC1 | |
| SCHEMBL20850204 | 0.88 | APP (0.32) | APPNPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20850205 | 0.87 | NPC1 (0.31) | MAPTNPC1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947212-B2 | Photoelectric conversion element, two-dimensional sensor, image sensor, and image pickup device | CANON KABUSHIKI KAISHA (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20190092743-A1 | PHOTOELECTRIC CONVERSION ELEMENT, TWO-DIMENSIONAL SENSOR, IMAGE SENSOR, AND IMAGE PICKUP DEVICE | CANON KABUSHIKI KAISHA (JP) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092743-A1 | PHOTOELECTRIC CONVERSION ELEMENT, TWO-DIMENSIONAL SENSOR, IMAGE SENSOR, AND IMAGE PICKUP DEVICE | NR2E3, CRY2, GPR3 | MAPT 3800/4885APP 1621/4885SLC16A3 3490/4885 |
| US-10947212-B2 | Photoelectric conversion element, two-dimensional sensor, image sensor, and image pickup device | NR2E3, CRY2, GPR3 | MAPT 3800/4885APP 1621/4885SLC16A3 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.